Sacituzumab Govitecan Shows Promise in Advanced Endometrial Cancer
By Elana Gotkine HealthDay Reporter
WEDNESDAY, Aug. 14, 2024 -- For patients with advanced endometrial cancer (EC), sacituzumab govitecan (SG), a trophoblast cell-surface antigen 2 (Trop-2)-directed antibody-drug conjugate, shows encouraging efficacy, according to a phase 2 study published online July 31 in the Journal of Clinical Oncology.
Alessandro D. Santin, M.D., from the Yale School of Medicine in New Haven, Connecticut, and colleagues conducted a phase 2 basket study to examine the efficacy and safety of SG in patients with advanced EC. Eligible patients received SG 10 mg/kg once on days 1 and 8 every three weeks; median follow-up was 5.8 months. The primary end point was the objective response rate.
Forty-one patients were enrolled at the data extraction date; the median previous therapies was three, and 85 percent of participants received previous chemotherapy and immunotherapy. The researchers found an objective response rate of 22 percent and a clinical benefit rate of 32 percent. The median duration of response was 8.8 months, and median progression-free survival was 4.8 months. For 39 patients, a Trop-2 exploratory analysis was conducted retrospectively. There was high expression of tumor Trop-2 protein in EC, with limited correlation seen with efficacy. Seventy-three percent of patients had grade ≥3 treatment-related adverse events (TRAEs). Discontinuation of study drugs due to TRAEs was 5 percent. There were two deaths, which were unrelated to SG.
"On the basis of the results from this trial, a randomized phase III study is planned," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Gilead Sciences, which manufactures sacituzumab govitecan and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted August 2024
Read this next
Transvaginal Ultrasound Triage Strategy for Endometrial Cancer Not Reliable for Black Women at Risk
WEDNESDAY, July 10, 2024 -- For Black adults at risk for endometrial cancer (EC), a transvaginal ultrasonography triage strategy is not reliable, according to a study published...
FDA Approves KEYTRUDA + Chemo for Primary Advanced, Recurrent Endometrial Carcinoma
FRIDAY, June 21, 2024 -- The U.S. Food and Drug Administration has approved Keytruda (pembrolizumab) plus chemotherapy as treatment for adult patients with primary advanced or...
White Women Overrepresented in Gynecologic Cancer Trials
TUESDAY, Dec. 12, 2023 -- White women are disproportionately represented in clinical trials for gynecologic cancers, according to a study published online Dec. 7 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.